What is the recommended pediatric dosing of fish oil (eicosapentaenoic acid and docosahexaenoic acid) based on age and weight?

Pediatric Fish Oil Dosing

For healthy children aged 2–18 years, administer 250 mg/day of combined EPA + DHA; for infants 6–24 months, use weight-based dosing of 10–12 mg/kg/day of DHA; and for infants 0–6 months, provide 100–200 mg/day of DHA. 1

Age-Specific Dosing Algorithms

Infants 0–6 Months

• Primary recommendation: 100–200 mg/day DHA as a fixed daily dose 1
• Critical caveat: EPA intake must remain lower than DHA intake in this age group to prioritize neurodevelopmental support 1
• Alternative weight-based calculation: 0.1–0.18% of total energy intake as DHA 1
• Korean guidelines specifically recommend 200 mg/day DHA for infants 0–5 months 1

Infants 6–24 Months

• Preferred approach: Weight-based dosing of 10–12 mg/kg body weight of DHA daily to accommodate rapid growth and variable body sizes 1
• Fixed-dose alternative: 70–100 mg/day DHA if weight-based calculation is impractical 1
• Rationale for weight-based dosing: This age group experiences the most rapid growth velocity, making fixed dosing less physiologically appropriate 1

Young Children 1–3 Years

• Standard recommendation: 250 mg/day EPA + DHA combined, endorsed by five major dietary standards 1
• Minimum adequate intake: 40 mg/day of EPA + DPA + DHA based on population median intakes 1
• Practical implementation: This aligns with EFSA guidance of one to two fatty-fish meals weekly starting at age 2 years 1

Older Children 4–12 Years

• Consensus dose: 250 mg/day EPA + DHA, supported by five technical scientific documents 1
• Acceptable range: 55–500 mg/day depending on age and regional standards 1
• Higher-end dosing (500 mg/day) applies specifically to children ≥10 years in some European guidelines 1
• Alternative escalating approach: 250–500 mg/day EPA + DHA starting at age 7 years 1

Adolescents 13–18 Years

• Standard recommendation: 250 mg/day EPA + DHA across major international guidelines 1
• Acceptable range: 70–500 mg/day based on regional standards 1
• Gender-specific Korean targets: 100–230 mg/day based on age and sex 1
• Optimal health targets (90th percentile intake): Approximately 610 mg/day for males and 430 mg/day for females aged ≥14 years 1

Safety and Upper Limits

Children and Adolescents (3–18 Years)

• Upper limit from Australia/New Zealand: 3 g/day EPA + DPA + DHA from combined food and supplement sources for all pediatric age groups beyond infancy 2
• Norwegian safety assessment: Insufficient evidence to conclude on safety of doses of 1.1 g/day DHA, 1.55 g/day EPA, or combined doses from supplements for children 3–18 years 2
• EFSA guidance: Supplemental intakes of DHA alone up to 1 g/day do not raise safety concerns for the general population, though it is unclear if this applies to all pediatric age groups 2

Infants

• No established upper limit for infants 0–6 months, but DHA within the human milk range up to 0.75% of energy (approximately 532 mg DHA) is considered safe 2
• Upper limit not determinable for infants according to Australia/New Zealand guidelines 2

Clinical Evidence Supporting Dosing

Absorption and Efficacy Data

• Dispersed fish oil is better absorbed than bolus administration: Infants receiving 11 mg/kg/day DHA from dispersed fish oil absorbed as much or more than those receiving 71 mg/kg/day DHA as a bolus 3
• High-dose supplementation (250 mg DHA + 60 mg EPA daily) from birth to 6 months significantly increased erythrocyte and plasma phospholipid DHA levels at 6 months 4
• Minimal supplementation (500 mg fish oil containing 112 mg DHA daily) for 9 weeks improved DHA status in malnourished children aged 8–30 months, increasing RBC DHA from 2.27% to 3.35% 5

Cardiovascular and Metabolic Effects

• Adolescent dosing of 1.5 g/day n-3 LCPUFA for 16 weeks (providing EPA + DHA) reduced systolic blood pressure by 3.8 mm Hg and diastolic blood pressure by 2.6 mm Hg in overweight boys aged 13–15 years 6
• Changes in RBC EPA content correlated inversely with blood pressure changes and directly with HDL cholesterol increases 6

Cognitive Outcomes

• Threshold for cognitive benefit: Daily supplementation ≥450 mg DHA + EPA and achieving an Omega-3 Index >6% makes efficacy on cognition more likely in typically developing children and adolescents 7
• Late infancy supplementation (3.4 mL/day fish oil from 9–12 months) affected infant attention in free-play testing and was associated with decreased systolic blood pressure 8

Key Implementation Principles

Formulation Matters

• Disperse fish oil in formula or food rather than administering as a bolus to optimize absorption, particularly in infants and young children 3
• Fish oil can be incorporated into bread or other foods for better compliance in older children 6

EPA:DHA Ratio Considerations

• For infants <6 months: DHA must predominate over EPA to support neurodevelopment 1
• For older children and adolescents: The EPA:DHA ratio appears less critical when adequate preformed DHA is supplied, though a ratio of 5:1–15:1 (LA:ALA) remains a useful dietary benchmark 1
• Higher EPA:DHA ratios may enhance anti-inflammatory effects: Meta-regression data suggest greater C-reactive protein reduction with higher EPA:DHA ratios, particularly in the 2–6 g/day supplementation range 9

Timing of Administration

• End-of-day consumption may optimize EPA and DHA incorporation into physiological fatty acid compositions, based on animal model data 10

Common Pitfalls to Avoid

• Do not use fixed dosing for infants 6–24 months when weight-based dosing (10–12 mg/kg/day DHA) is feasible, as this age group has highly variable growth rates 1
• Do not exceed EPA relative to DHA in infants <6 months, as this may compromise neurodevelopmental support 1
• Do not assume all fish oil supplements are equally bioavailable—dispersed formulations are superior to bolus administration in young children 3
• Do not rely solely on dietary intake in populations with low seafood consumption—supplementation or fortified foods may be necessary to achieve target intakes 2